Article

Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats

Lilly Research Laboratories, Eli Lilly, Indianapolis, Indiana, United States
Journal of Pharmacology and Experimental Therapeutics (Impact Factor: 3.86). 12/2004; 311(2):576-84. DOI: 10.1124/jpet.104.070656
Source: PubMed

ABSTRACT 5-Hydroxytryptamine (serotonin) (5-HT) and norepinephrine (NE) are implicated in modulating descending inhibitory pain pathways in the central nervous system. Duloxetine is a selective and potent dual 5-HT and NE reuptake inhibitor (SNRI). The ability of duloxetine to antagonize 5-HT depletion in para-chloramphetamine-treated rats was comparable with that of paroxetine, a selective serotonin reuptake inhibitor (SSRI), whereas its ability to antagonize NE depletion in alpha-methyl-m-tyrosine-treated rats was similar to norepinephrine reuptake inhibitors (NRIs), thionisoxetine or desipramine. In this paradigm, duloxetine was also more potent than other SNRIs, including venlafaxine or milnacipran and amitriptyline. Low doses of the SSRI paroxetine or the NRI thionisoxetine alone did not have an effect on late phase paw-licking pain behavior in the formalin model of persistent pain; however, when combined, significantly attenuated this pain behavior. Duloxetine (3-15 mg/kg intraperitoneal) significantly attenuated late phase paw-licking behavior in a dose-dependent manner in the formalin model and was more potent than venlafaxine, milnacipran, and amitriptyline. These effects of duloxetine were evident at doses that did not cause neurologic deficits in the rotorod test. Duloxetine (5-30 mg/kg oral) was also more potent and efficacious than venlafaxine and milnacipran in reversing mechanical allodynia behavior in the L5/L6 spinal nerve ligation model of neuropathic pain. Duloxetine (3-30 mg/kg oral) was minimally efficacious in the tail-flick model of acute nociceptive pain. These data suggest that inhibition of both 5-HT and NE uptake may account for attenuation of persistent pain mechanisms. Thus, duloxetine may have utility in treatment of human persistent and neuropathic pain states.

0 Followers
 · 
50 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Los pacientes con trastornos depresivos frecuentemente manifiestan quejas somáticas como, por ejemplo, dolor. La mejoría en la percepción del dolor que se produce en pacientes con síntomas depresivos tratados con antidepresivos puede deberse a una mejoría en la depresión. Varias publicaciones indican que la actividad antinociceptiva de los antidepresivos es independiente de la mejoría del estado de ánimo y que está en relación con el efecto de estos fármacos en vías noradrenérgicas y serotoninérgicas ascendentes y descendentes.En modelos animales, sustancias que inhiben selectivamente la recaptación de noradrenalina disminuyen la percepción del dolor; compuestos que inhiben de manera selectiva la recaptación de serotonina no tienen ese efecto pero potencian el efecto antinociceptivo de las que inhiben la recaptación de noradrenalina.Disminuyendo la percepción del dolor se contribuye a mejorar los síntomas depresivos que pudieran coexistir. Una mejoría en los síntomas depresivos que pudieran magnificar la percepción del dolor contribuiría a disminuir esta última; el efecto de algunos fármacos en el sistema límbico puede conducir a mejorar tanto la percepción del dolor como el estado de ánimo.Duloxetina posee acción dual como inhibidor de la recaptación de serotonina y noradrenalina. Investigaciones recientes señalan que no es possible discernir entre el efecto analgésico y antidepresivo de duloxetina. Otros estudios evidencian que el efecto de duloxetina en la percepción del dolor es independiente del efecto antidepresivo. La evolución del caso presentado parece apoyar la hipótesis de que duloxetina contribuye de manera independiente a la mejoría de ambos tipos de síntomas.
    01/2008; 15(1):23-26. DOI:10.1016/S1134-5934(08)71117-5
  • [Show abstract] [Hide abstract]
    ABSTRACT: Several antidepressants have been used to treat severe pain in clinics. Recently, it has been shown that ellagic acid (EA), a major constituent of pomegranate juice, produced antinociceptive and anti-inflammatory effect through the central and peripheral sites of action.
    Pharmacological reports: PR 06/2015; 67(3). DOI:10.1016/j.pharep.2014.11.004 · 2.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Metabolomics was applied to a C57BL/6N mouse model of chronic unpredictable mild stress (CMS). Such mice were treated with two antidepressants from different categories: fluoxetine and imipramine. Metabolic profiling of the hippocampus was performed using gas chromatography-mass spectrometry analysis on samples prepared under optimized conditions, followed by principal component analysis, partial least squares-discriminant analysis, and pair-wise orthogonal projections to latent structures discriminant analyses. Body weight measurement and behavior tests including an open field test and the forced swimming test were completed with the mice as a measure of the phenotypes of depression and antidepressive effects. As a result, 23 metabolites that had been differentially expressed among the control, CMS, and antidepressant-treated groups demonstrated that amino acid metabolism, energy metabolism, adenosine receptors, and neurotransmitters are commonly perturbed by drug treatment. Potential predictive markers for treatment effect were identified: myo-inositol for fluoxetine and lysine and oleic acid for imipramine. Collectively, the current study provides insights into the molecular mechanisms of the antidepressant effects of two widely used medications.
    Scientific Reports 03/2015; 5:8890. DOI:10.1038/srep08890 · 5.08 Impact Factor